4 terminated, 2 completed. 6 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Terminated 4, Completed 2 |
| Phase 2 | 4 | Terminated 3, Completed 1 |
Follow IT-101: new trials by email Literature Review of IT-101 trials Research Report on IT-101
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer EP0057, olaparib, CT scan - Urothelial Carcinoma, Urothelial Cancer | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 45 | 2016-05-09 | 2026-08-13 |
| Alternative Dosing for CRLX101(NLG207) Alone, With Avastin and With mFOLFOX6 in Advanced Solid Tumors CRLX101, Bevacizumab, mFOLFOX6 - Solid Tumors | Phase 1 | Terminated | NewLink Genetics Corporation | 41 | 2015-10-01 | 2020-05-28 |
| A Study of CRLX101(NLG207) in Combination With Weekly Paclitaxel in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer CRLX101, Paclitaxel - Ovarian Cancer | Phase 1 / Phase 2 | Terminated | NewLink Genetics Corporation | 30 | 2015-07-01 | 2026-06-18 |
| Neoadjuvant Chemoradiotherapy With CRLX-101 and Capecitabine for Rectal Cancer CRLX101, Capecitabine, Radiotherapy - Rectal Cancer | Phase 1 / Phase 2 | Terminated | UNC Lineberger Comprehensive Cancer Center | 32 | 2013-12-01 | 2020-11-03 |
| CRLX101 Plus Bevacizumab in Advanced RCC CRLX101 (Cerulean), Bevacizumab - Renal Cell Carcinoma | Phase 1 | Completed | Abramson Cancer Center at Penn Medicine | 22 | 2012-06-01 | 2018-08-29 |
| Study of CRLX101 (NLG207) in the Treatment of Advanced Solid Tumors Camptothecin (CPT) conjugated to a linear, cyclodextrin-based polymer - Cancer, Solid Tumor | Phase 1 / Phase 2 | Completed | NewLink Genetics Corporation | 62 | 2006-05-01 | 2020-05-28 |
Lung Neoplasms (2) · Ovarian Neoplasms (2) · Prostatic Neoplasms (2) · Breast Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Carcinoma, Transitional Cell (1) · Colonic Neoplasms (1) · Colorectal Neoplasms (1) · Endometrial Neoplasms (1) · Melanoma (1) · Neoplasm Metastasis (1) · Neoplasms (1) · Pancreatic Neoplasms (1) · Rectal Neoplasms (1)
NewLink Genetics Corporation (3) · Abramson Cancer Center at Penn Medicine (1) · National Cancer Institute (NCI) (1) · UNC Lineberger Comprehensive Cancer Center (1)
United States (6)
Andrew Wang, MD (1) · Anish Thomas, M.D. (1) · Glenn Weiss, M.D. (1) · Jeffrey D. Neidhart, M.D. (1) · Naomi M Haas, MD (1) · NewLink Ge (1) · Yun Yen, M.D., Ph.D. (1)
PMID 27784746, PMID 30858085, PMID 32897402, PMID 33390325, PMID 42820295